AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11729746 — intervention group
Group type: EXPERIMENTAL
Intervention: AV decompression
Number of subjects: 40
Study 11729746 — intervention group
Group type: COMPARATOR
Intervention: Control (no AV decompression)
Number of subjects: 40
Study 10225782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment by selective adsorption followed by intravenous IgG
Number of subjects: 45
Study 10225782 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 45
Study 10225782 — intervention group
Group type: COMPARATOR
Intervention: Selective adsorption using a tryptophan-linked polyvinyl alcohol gel adsorbent
Number of subjects: 45
Study 7716421 — intervention group
Group type: EXPERIMENTAL
Intervention: High competition sport group (n=52)
Number of subjects: 102
Study 7716421 — intervention group
Group type: COMPARATOR
Intervention: University reference group (n=50)
Number of subjects: 102
Study 2825746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg) inhalation in volunteers and patients
Number of subjects: 18
Study 2825746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (1 mg kg‐1) oral administration in healthy volunteers
Number of subjects: 18
Study 2825746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (0.2 microgram kg‐1 for 30 min) intravenous administration in healthy volunteers
Number of subjects: 18
Study 2825746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg) multiple dosing four times daily for 7 days in volunteers
Number of subjects: 18
Study 2825746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg) multiple dosing four times daily for 1, 6, and 12 months in patients
Number of subjects: 18
Study 29029563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, transdiagnostic preventive intervention based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Number of subjects: 0
Study 27770819 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAS intervention schools (n=20)
Number of subjects: 40
Study 27770819 — intervention group
Group type: COMPARATOR
Intervention: Usual care schools (n=20)
Number of subjects: 40
Study 24362411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with metformin (1000 mg BID) and liraglutide (1.2 mg QD s.c.)
Number of subjects: 40
Study 24362411 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (1.2 mg QD s.c.)
Number of subjects: 40
Study 24362411 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg BID)
Number of subjects: 40
Study 22130118 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended run-in group (4 weeks of pre-TQD varenicline)
Number of subjects: 60
Study 22130118 — intervention group
Group type: COMPARATOR
Intervention: Standard run-in group (3 weeks of placebo, 1 week of pre-TQD varenicline)
Number of subjects: 60
Study 20432794 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) including CPAP and NIPPV
Number of subjects: 0
Study 20432794 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV protocol in use at the University Lewisham Hospital
Number of subjects: 0
Study 18208361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pneumatic and ultrasonic lithotrite (PUL)
Number of subjects: 30
Study 18208361 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasonic lithotrite (SUL)
Number of subjects: 30
Study 15867182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 949
Study 15867182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 12637459 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m² plus docetaxel 75 mg/m² (AT)
Number of subjects: 429
Study 12637459 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (AC)
Number of subjects: 429
Study 11078283 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta irradiation
Number of subjects: 100
Study 11078283 — intervention group
Group type: COMPARATOR
Intervention: Gamma irradiation
Number of subjects: 100
Study 11078283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8626853 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sc GH treatment at a dose of 0.2 or 0.3 IU/kg
Number of subjects: 50
Study 8626853 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 50
Study 10135638 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured review form
Number of subjects: 25
Study 10135638 — intervention group
Group type: COMPARATOR
Intervention: Historic worksheet
Number of subjects: 25
Study 3569765 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid enema
Number of subjects: 153
Study 3569765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 29216569 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm handoff
Number of subjects: 25
Study 29216569 — intervention group
Group type: COMPARATOR
Intervention: Fax referral
Number of subjects: 25
Study 27165954 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission heart rate ≥85 bpm
Number of subjects: 3185
Study 27165954 — intervention group
Group type: COMPARATOR
Intervention: Admission heart rate
Number of subjects: 3185
Study 24220224 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (15 min) plus conventional therapy
Number of subjects: 30
Study 24220224 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study 20609531 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner-delivered brief advice
Number of subjects: 1334
Study 20609531 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated tailored letters
Number of subjects: 1334
Study 18261177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir prophylaxis
Number of subjects: 148
Study 15699836 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-10 (1, 10, or 25 microg/kg) administered 2 mins before lipopolysaccharide (4 ng/kg)
Number of subjects: 24
Study 15699836 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-10 (1, 10, or 25 microg/kg) administered 2 hrs before lipopolysaccharide (4 ng/kg)
Number of subjects: 24
Study 15699836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lipopolysaccharide alone)
Number of subjects: 24
Study 15699836 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-10 (1, 10, or 25 microg/kg)
Number of subjects: 24
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750mg once daily for 7-14 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg once daily for 7-14 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750mg once daily for 5 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg once daily for 7 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg once daily for 10-14 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg once daily for 28 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg once daily for 7-10 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750mg for 7-14 days
Number of subjects: 0
Study 14664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study 11392068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 120
Study 11392068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 120
Study 11392068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg
Number of subjects: 120
Study 11392068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9% 4 mL)
Number of subjects: 120
Study 8806903 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY u 3405 (50 mg)
Number of subjects: 11
Study 8806903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1634480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg tablet twice daily
Number of subjects: 40
Study 1634480 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 1 g four times a day
Number of subjects: 40
Study 4067974 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 28% oxygen for 2-hour periods
Number of subjects: 6
Study 4067974 — intervention group
Group type: COMPARATOR
Intervention: Breathing air for 2-hour periods
Number of subjects: 6
Study 4067974 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of oxygen
Number of subjects: 6
Study 29778861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic optimization
Number of subjects: 401
Study 29778861 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic optimization
Number of subjects: 401
Study 30006211 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in outdoor time
Number of subjects: 145
Study 27687350 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP blocks (n = 20)
Number of subjects: 60
Study 27687350 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTAP blocks (n = 20)
Number of subjects: 60
Study 27687350 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) only (n = 20)
Number of subjects: 60
Study 24846173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) system in active mode
Number of subjects: 0
Study 24846173 — intervention group
Group type: COMPARATOR
Intervention: Vagal nerve stimulation (VNS) system in inactive mode
Number of subjects: 0
Study 24846173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) system (after 6 months)
Number of subjects: 0
Study 22529197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) overfeeding diet for 5 days
Number of subjects: 46
Study 22529197 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 46
Study 21035069 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocanalicular silicone intubation (MCI)
Number of subjects: 57
Study 21035069 — intervention group
Group type: COMPARATOR
Intervention: Bicanalicular silicone intubation (BCI)
Number of subjects: 57
Study 18443868 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer (natural force feedback)
Number of subjects: 19
Study 18443868 — intervention group
Group type: COMPARATOR
Intervention: VR trainer (no force feedback)
Number of subjects: 19
Study 18443868 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer and VR trainer
Number of subjects: 19
Study 16045136 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 47
Study 16045136 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 47
Study 16045136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthesia types
Number of subjects: 47
Study 12237770 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised patients treated with local excision and radiotherapy
Number of subjects: 910
Study 12237770 — intervention group
Group type: COMPARATOR
Intervention: Non-entered patients treated with local excision and radiotherapy
Number of subjects: 910
Study 12237770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with local excision alone (both groups)
Number of subjects: 910
Study 10406187 — intervention group
Group type: EXPERIMENTAL
Intervention: AdoMet (1200 mg/day, orally)
Number of subjects: 123
Study 10406187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 7756795 — intervention group
Group type: EXPERIMENTAL
Intervention: Human surfactant therapy
Number of subjects: 0
Study 7756795 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 7756795 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 0
Study 2256759 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 micrograms)
Number of subjects: 16
Study 2256759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 16
Study 2256759 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic daily treatment with octreotide acetate
Number of subjects: 16
Study 375460 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment (3 days before operation and 3 days a fortnight thereafter)
Number of subjects: 318
Study 375460 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 318
Study 31941389 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep inspirations (DIs) - 60 DIs to total lung capacity immediately pre-high-fat meal (HFM)
Number of subjects: 16
Study 31941389 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no DIs pre-HFM)
Number of subjects: 16
Study 30740923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral medial rectus plication (BMRP)
Number of subjects: 55
Study 30740923 — intervention group
Group type: COMPARATOR
Intervention: Bilateral medial rectus resection (BMRR)
Number of subjects: 55
Study 26895152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturated Latino parents (English-speaking)
Number of subjects: 686
Study 26895152 — intervention group
Group type: EXPERIMENTAL
Intervention: English-speaking Latino parents
Number of subjects: 686
Study 26895152 — intervention group
Group type: COMPARATOR
Intervention: Spanish-speaking Latino parents and non-Latino white parents
Number of subjects: 686
Study 26895152 — intervention group
Group type: COMPARATOR
Intervention: Less acculturated Latino parents
Number of subjects: 686
Study 25808050 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis prepared platelets (APCs)
Number of subjects: 15
Study 25808050 — intervention group
Group type: COMPARATOR
Intervention: Random donor platelets (RDPs)
Number of subjects: 15
Study 23085682 — intervention group
Group type: EXPERIMENTAL
Intervention: SAME macaroni and cheese
Number of subjects: 61
Study 23085682 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMILAR types of macaroni and cheese
Number of subjects: 61
Study 23085682 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIETY of high‐energy‐dense foods
Number of subjects: 61
Study 23085682 — intervention group
Group type: EXPERIMENTAL
Intervention: SAME high‐energy‐dense entrees
Number of subjects: 61
Study 23085682 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMILAR high‐energy‐dense entrees
Number of subjects: 61
Study 23085682 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIETY of high‐energy‐dense entrees
Number of subjects: 61
Study 18832745 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 505
Study 18832745 — intervention group
Group type: COMPARATOR
Intervention: Whites
Number of subjects: 505
Study 17584349 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy (8 weekly sessions)
Number of subjects: 32
Study 17584349 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 32
Study 15101598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented implant‐supported single‐tooth crown
Number of subjects: 12
Study 15101598 — intervention group
Group type: COMPARATOR
Intervention: Screw‐retained implant‐supported single‐tooth crown
Number of subjects: 12
Study 11434356 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (0.1 g/kg body weight/day)
Number of subjects: 11
Study 11434356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9504626 — intervention group
Group type: COMPARATOR
Intervention: Previously treated MM patients on treatment (n = 60)
Number of subjects: 268
Study 9504626 — intervention group
Group type: COMPARATOR
Intervention: Previously treated MM patients off treatment (n = 45)
Number of subjects: 268
Study 9504626 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed MM patients (n = 58)
Number of subjects: 268
Study 9504626 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19+ cell levels above 125/microl
Number of subjects: 268
Study 9504626 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with >395 CD4 cells/microl
Number of subjects: 268
Study 7522379 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HES 200/0.5
Number of subjects: 30
Study 7522379 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.5
Number of subjects: 30
Study 7522379 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.6‐0.66
Number of subjects: 30
Study 3288846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone substitution therapy with 17 beta‐oestradiol
Number of subjects: 5
Study 3288846 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 5
Study 239800 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0
Study 239800 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 0
Study 239800 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 239800 — intervention group
Group type: COMPARATOR
Intervention: Control baseline conditions
Number of subjects: 0
Study 239800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological stress
Number of subjects: 0
Study 31977010 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA
Number of subjects: 3755
Study 31977010 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3755
Study 31620079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation (FMT)
Number of subjects: 42
Study 31620079 — intervention group
Group type: COMPARATOR
Intervention: Control (no FMT)
Number of subjects: 42
Study 31620079 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 42
Study 28444240 — intervention group
Group type: EXPERIMENTAL
Intervention: tOPV
Number of subjects: 614
Study 28444240 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 614
Study 23253638 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 8468
Study 23253638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8468
Study 23235499 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Voice Response (AVR) system alone
Number of subjects: 119
Study 23235499 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR with strategies to manage symptoms and adherence
Number of subjects: 119
Study 23235499 — intervention group
Group type: EXPERIMENTAL
Intervention: AVR with strategies to manage adherence
Number of subjects: 119
Study 23235499 — intervention group
Group type: COMPARATOR
Intervention: AVR intervention alone
Number of subjects: 119
Study 21240480 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus (AP)
Number of subjects: 17
Study 21240480 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumatic (VM)
Number of subjects: 17
Study 21240480 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchro‐Breathe (SB)
Number of subjects: 17
Study 21240480 — intervention group
Group type: COMPARATOR
Intervention: Evohaler pMDI (EH)
Number of subjects: 17
Study 17329954 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion with sagittal plane correction using posterior instrumentation (3rd generation instrumentation system transpedicular screws)
Number of subjects: 40
Study 17329954 — intervention group
Group type: COMPARATOR
Intervention: Additional reduction of anterior slippage
Number of subjects: 40
Study 12656701 — intervention group
Group type: EXPERIMENTAL
Intervention: gonadotropin‐releasing hormone agonist/estradiol group (n = 9)
Number of subjects: 21
Study 12656701 — intervention group
Group type: COMPARATOR
Intervention: gonadotropin‐releasing hormone agonist/placebo group (n = 12)
Number of subjects: 21
Study 11152083 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-sensitive modifications to the Duke University Rice Diet (1000-calorie/day)
Number of subjects: 44
Study 11152083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 1540452 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 1540452 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0
Study 1540452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine and bupivacaine
Number of subjects: 0
Study 1540452 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 4087288 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern
Number of subjects: 0
Study 4087288 — intervention group
Group type: COMPARATOR
Intervention: Type B behavior pattern
Number of subjects: 0
Study 31009438 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 18
Study 31009438 — intervention group
Group type: COMPARATOR
Intervention: Control - no stretching (CON)
Number of subjects: 18
Study 30536149 — intervention group
Group type: EXPERIMENTAL
Intervention: RECAPP‐XPR application
Number of subjects: 273
Study 30536149 — intervention group
Group type: COMPARATOR
Intervention: Snapchat application
Number of subjects: 273
Study 30039905 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed loading with 45 Ncm insertion torque (Group 1)
Number of subjects: 30
Study 30039905 — intervention group
Group type: COMPARATOR
Intervention: Immediate loading with above 65 Ncm insertion torque (Group 2)
Number of subjects: 30
Study 30039905 — intervention group
Group type: COMPARATOR
Intervention: All-on-4 concept (control for comparison)
Number of subjects: 30
Study 27470610 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive communication
Number of subjects: 129
Study 27470610 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plan
Number of subjects: 129
Study 27470610 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 129
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.2 μg of rhFSH
Number of subjects: 265
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9 μg of rhFSH
Number of subjects: 265
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.6 μg of rhFSH
Number of subjects: 265
Study 25256937 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.3 μg of rhFSH
Number of subjects: 265